Summary
Alnylam Pharmaceuticals, Inc. reported a significant increase in total revenues for the third quarter and first nine months of 2023, driven by strong growth in net product revenues and substantial collaboration revenues, particularly from the new Roche agreement and an early clinical milestone from Regeneron. Net product revenues saw a notable increase of 35% year-over-year in Q3, primarily due to the launch and uptake of AMVUTTRA, offsetting a decline in ONPATTRO sales as patients switched to the newer therapy. The company also reported positive momentum across its other key products, GIVLAARI and OXLUMO. Operationally, the company's focus remains on advancing its pipeline, with significant R&D expenses supporting various clinical programs. Despite an increase in Cost of Goods Sold, largely due to an inventory impairment related to ONPATTRO's ATTR cardiomyopathy indication, the company achieved a net income of $147.8 million in Q3 2023, a significant turnaround from a net loss in the prior year's quarter. This improved profitability reflects the substantial collaboration revenue and disciplined expense management. The company maintains sufficient liquidity and believes its current cash and cash equivalents will support operations for at least the next 12 months.
Financial Highlights
48 data points| Revenue | $750.53M |
| Cost of Revenue | $79.47M |
| Gross Profit | $671.06M |
| R&D Expenses | $253.18M |
| SG&A Expenses | $199.18M |
| Operating Expenses | $536.66M |
| Operating Income | $213.87M |
| Interest Expense | $30.89M |
| Net Income | $147.75M |
| EPS (Basic) | $1.18 |
| EPS (Diluted) | $1.15 |
| Shares Outstanding (Basic) | 125.22M |
| Shares Outstanding (Diluted) | 131.34M |
Key Highlights
- 1Total revenues surged by 184% year-over-year to $750.5 million in Q3 2023, primarily driven by a substantial $311.3 million upfront payment from the Roche collaboration for zilebesiran.
- 2Net product revenues increased by 35% to $313.2 million in Q3 2023, with AMVUTTRA showing strong growth (489% increase), offsetting a decline in ONPATTRO sales.
- 3The company reported a net income of $147.8 million for Q3 2023, a significant improvement from a net loss of $405.9 million in Q3 2022, reflecting the impact of increased revenues and effective cost management.
- 4Research and development expenses increased by 3% to $253.2 million in Q3 2023, primarily due to increased clinical trial activities, particularly for zilebesiran and ALN-TTRsc04.
- 5Selling, general and administrative expenses decreased by 16% to $199.2 million in Q3 2023, mainly due to lower stock-based compensation expenses.
- 6The company ended the quarter with strong liquidity, holding $1.03 billion in cash and cash equivalents and $1.36 billion in marketable debt securities, providing ample resources for ongoing operations and development.